Search research articles
Contact Us
Filters
Showing results (51-60 of 81) with videos related to
Page
of 9
Sort By:
Cancer Chemotherapy and Pharmacology
|
March 7, 2009
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial
Carmela Pisano, Alessandro Morabito, Roberto Sorio, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
November 10, 2019
Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion
Michele Minopoli, Giovanni Botti, Vincenzo Gigantino, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 23, 2022
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups
Clorinda Schettino, Lucia Musacchio, Michele Bartoletti, et al.
Cancers
|
August 14, 2020
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience
Valentina Tuninetti, Marilena Di Napoli, Eleonora Ghisoni, et al.
Gynecologic Oncology
|
March 30, 2021
Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database
Francesca Falcone, Enrico Breda, Gabriella Ferrandina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2023
Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994
Gemma G Kenter, Stefano Greggi, Ignace Vergote, et al.
Oncology
|
June 20, 2014
Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9)
Francesca Esposito, Sabrina Chiara Cecere, Francescapaola Magazzino, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
June 26, 2022
Assessing the role of minimally invasive radical hysterectomy for early-stage cervical cancer
Giorgio Bogani, Violante Di Donato, Ludovico Muzii, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 2, 2020
Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey
Stefano Greggi, Francesca Falcone, Cono Scaffa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2004
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study
Sabino De Placido, Giovanni Scambia, Giovanni Di Vagno, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 81) with videos related to
Sort By:
Page
of 9
Cancer Chemotherapy and Pharmacology
|
March 7, 2009
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial
Carmela Pisano, Alessandro Morabito, Roberto Sorio, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
November 10, 2019
Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion
Michele Minopoli, Giovanni Botti, Vincenzo Gigantino, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 23, 2022
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups
Clorinda Schettino, Lucia Musacchio, Michele Bartoletti, et al.
Cancers
|
August 14, 2020
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience
Valentina Tuninetti, Marilena Di Napoli, Eleonora Ghisoni, et al.
Gynecologic Oncology
|
March 30, 2021
Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database
Francesca Falcone, Enrico Breda, Gabriella Ferrandina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2023
Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994
Gemma G Kenter, Stefano Greggi, Ignace Vergote, et al.
Oncology
|
June 20, 2014
Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9)
Francesca Esposito, Sabrina Chiara Cecere, Francescapaola Magazzino, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
June 26, 2022
Assessing the role of minimally invasive radical hysterectomy for early-stage cervical cancer
Giorgio Bogani, Violante Di Donato, Ludovico Muzii, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 2, 2020
Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey
Stefano Greggi, Francesca Falcone, Cono Scaffa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2004
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study
Sabino De Placido, Giovanni Scambia, Giovanni Di Vagno, et al.
Page
of 9